Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 14/20 | 0.49 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.42 |
| ▸ | APP | P05067 | 2/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12877821 | 0.90 | APP (0.52) | BRD4PTGDR2APPCTSSCTSK | |
| SCHEMBL1202341 | 0.88 | APP (0.48) | BRD4APP | |
| SCHEMBL1202688 | 0.88 | APP (0.46) | BRD4APP | |
| SCHEMBL1201622 | 0.88 | APP (0.45) | BRD4PTGDR2APP | |
| SCHEMBL1203008 | 0.87 | APP (0.43) | BRD4PTGDR2APP | |
| SCHEMBL1202972 | 0.86 | APP (0.43) | BRD4PTGDR2APP | |
| SCHEMBL1202280 | 0.86 | APP (0.43) | BRD4APP | |
| SCHEMBL1202951 | 0.86 | APP (0.44) | BRD4APPCTSSCTSK | |
| SCHEMBL8044676 | 0.85 | APP (0.59) | PTGDR2APP | |
| SCHEMBL1201791 | 0.83 | APP (0.42) | BRD4PTGDR2APP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2011-02-17 | — | — | US | disclosed |
| WO-2009036428-A2 | 1,3,4-TRISUBSTITUTED BENZENES | ENVIVO PHARMACEUTICALS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110040094-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | BRD4 19/4885PTGDR2 1817/4885APP 4/4885 |
| US-20140187786-A1 | 1,3,4-TRISUBSTITUTED BENZENES | BACE1, BACE2, PSEN1 | BRD4 19/4885PTGDR2 1817/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.